{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:06:02Z","timestamp":1793397962939,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013845","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000}}],"reference-count":139,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013845.pub2","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T12:09:47Z","timestamp":1661429387000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Memantine for autism spectrum disorder"],"prefix":"10.1002","volume":"2022","author":[{"given":"Amanda","family":"Brignell","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Monash University; Melbourne Australia"},{"name":"Developmental Paediatrics; Monash Children's Hospital; Melbourne Australia"},{"name":"Department of Speech Pathology; Australian Catholic University; Melbourne Australia"},{"name":"Murdoch Children's Research Institute; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Marraffa","sequence":"additional","affiliation":[{"name":"Murdoch Children's Research Institute; Melbourne Australia"},{"name":"Department of Paediatrics; University of Melbourne; Melbourne Australia"},{"name":"Neurodevelopment and Disability; The Royal Children's Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Monash University; Melbourne Australia"},{"name":"Developmental Paediatrics; Monash Children's Hospital; Melbourne Australia"},{"name":"Murdoch Children's Research Institute; Melbourne Australia"},{"name":"Department of Paediatrics; University of Melbourne; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"May","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2015.0146","article-title":"Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension","volume":"27","author":"Aman","year":"2017","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0002|cit2","unstructured":"Study of pharmacokinetics, safety, efficacy, and tolerability of memantine in children with autism clinicaltrials.gov\/ct2\/show\/NCT00872898"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4103\/abr.abr_100_18","article-title":"Efficacy of memantine as adjunct therapy for autism spectrum disorder in children aged <14 years","volume":"7","author":"Karahmadi","year":"2018","journal-title":"Advanced Biomedical Research"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0004|cit4","volume-title":"A double-blind placebo-controlled trial of memantine vs placebo in children with autism spectrum disorder (ASD) targeting memory and motor planning [MS thesis]","author":"Bader","year":"2016"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0005|cit5","unstructured":"A multi-site double-blind placebo-controlled trial of memantine versus placebo in children with autism (MEM) clinicaltrials.gov\/ct2\/show\/NCT01372449"},{"issue":"7","key":"10.1002\/14651858.CD013845.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/cap.2021.0010","article-title":"Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder","volume":"31","author":"Soorya","year":"2021","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1017\/S1461145712000880","article-title":"Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Ghaleiha","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0008|cit8","unstructured":"Memantine in the treatment of autism www.irct.ir\/trial\/860"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0009|cit9","unstructured":"A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-001568-31\/BE"},{"issue":"8","key":"10.1002\/14651858.CD013845.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1177\/1362361318824103","article-title":"Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies","volume":"23","author":"Hardan","year":"2019","journal-title":"Autism"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0011|cit11","unstructured":"Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine clinicaltrials.gov\/ct2\/show\/NCT01592747"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0012|cit12","unstructured":"Safety study of memantine in pediatric patients with autism, Asperger's disorder or pervasive developmental disorder not otherwise specified (PDD-NOS) clinicaltrials.gov\/ct2\/show\/NCT01592773"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0013|cit13","unstructured":"Memantine in adult autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT01078844"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0014|cit14","unstructured":"Cortical metrics assessment outcome measure development in autism with memantine treatment clinicaltrials.gov\/ct2\/show\/NCT02353130"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013845.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"S729","DOI":"10.1016\/S0924-977X(16)31879-X","article-title":"The safety and efficacy of memantine hydrochloride versus placebo for children under 3 years old with autism spectrum disorders","volume":"26","author":"Martsenkovsky","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0016|cit16","unstructured":"Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-003080-38\/DE"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"H\u00e4ge A Banaschewski T Buitelaar JK Dijkhuizen RM Franke B Lythgoe DJ Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) \u2013 study protocol for a randomised controlled trial Trials 2016 17 1\u00a0 141 10.1186\/s13063-016-1266-8 26983548","DOI":"10.1186\/s13063-016-1266-8"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0018|cit18","unstructured":"Behavioral and neural response to memantine in adolescents with autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT01972074"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0019|cit19","unstructured":"Memantine for the treatment of social deficits in youth with disorders of impaired social interactions clinicaltrials.gov\/ct2\/show\/NCT03553875"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0020|cit20","volume-title":"Aberrant Behavior Checklist Manual","author":"Aman","year":"2017"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1362361314542955","article-title":"Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder","volume":"19","author":"Anagnostou","year":"2015","journal-title":"Autism"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0022|cit22","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0023|cit23","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edition, revised","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0024|cit24","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0025|cit25","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th edition, text revision","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0026|cit26","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder Cochrane Database of Systematic Reviews 2021 2 10.1002\/14651858.CD013457.pub2 33583058","DOI":"10.1002\/14651858.CD013457.pub2"},{"issue":"6","key":"10.1002\/14651858.CD013845.pub2-BIB0028|cit28","first-page":"573","article-title":"Autism: an overview of genetic aetiology","volume":"86","author":"Bayou","year":"2008","journal-title":"La Tunisie M\u00e9dicale"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0029|cit29","volume-title":"Family Quality of Life Scale","author":"Beach Center on Disabilities","year":"2006"},{"issue":"7","key":"10.1002\/14651858.CD013845.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1162\/jocn_a_00383","article-title":"Nicotinic acetylcholine receptors contribute to learning-induced metaplasticity in the hippocampus","volume":"25","author":"Becker","year":"2013","journal-title":"Journal of Cognitive Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1087054714538656","article-title":"Memantine in the treatment of executive function deficits in adults with ADHD: a pilot-randomized double-blind controlled clinical trial","volume":"21","author":"Biederman","year":"2017","journal-title":"Journal of Attention Disorders"},{"issue":"21","key":"10.1002\/14651858.CD013845.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"e3737","DOI":"10.1097\/MD.0000000000003737","article-title":"Population-based prevalence of intellectual disability and autism spectrum disorders in western Australia: a comparison with previous estimates","volume":"95","author":"Bourke","year":"2016","journal-title":"Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013845.pub2-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011612.pub2","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","author":"Caddy","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10519-019-09987-2","article-title":"On the nature of monozygotic twin concordance and discordance for autistic trait severity: a quantitative analysis","volume":"50","author":"Castelbaum","year":"2020","journal-title":"Behavior Genetics"},{"issue":"9","key":"10.1002\/14651858.CD013845.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007849.pub2","article-title":"Acupuncture for autism spectrum disorders (ASD)","author":"Cheuk","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/0883073807302611","article-title":"Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability","volume":"22","author":"Chez","year":"2007","journal-title":"Journal of Child Neurology"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0038|cit38","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0039|cit39","volume-title":"Conners' Rating Scales \u2013 Revised","author":"Conners","year":"1997"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0040|cit40","volume-title":"Social Responsiveness Scale","author":"Constantino","year":"2011"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0041|cit41","unstructured":"Covidence 2020 Veritas Health Innovation 2020"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0042|cit42","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"Pt A","key":"10.1002\/14651858.CD013845.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemporary Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD013845.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1517\/14656566.2012.674110","article-title":"Pharmacotherapy to control behavioral symptoms in children with autism","volume":"13","author":"Doyle","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0046|cit46","volume-title":"Peabody Picture Vocabulary Test","author":"Dunn","year":"2018"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/1362361315627136","article-title":"The neuroanatomy of autism spectrum disorder: an overview of structural neuroimaging findings and their translatability to the clinical setting","volume":"21","author":"Ecker","year":"2017","journal-title":"Autism"},{"issue":"7109","key":"10.1002\/14651858.CD013845.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/aur.239","article-title":"Global prevalence of autism and other pervasive developmental disorders","volume":"5","author":"Elsabbagh","year":"2012","journal-title":"Autism Research"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD013845.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00002018-200831070-00003","article-title":"Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials","volume":"31","author":"Farlow","year":"2008","journal-title":"Drug Safety"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40265-013-0021-7","article-title":"Pharmacotherapy for the core symptoms in autistic disorder: current status of the research","volume":"73","author":"Farmer","year":"2013","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0053|cit53","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs generalized anxiety disorder: an open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/cap.2006.0044","article-title":"A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit\/hyperactivity disorder combined type","volume":"17","author":"Findling","year":"2007","journal-title":"Journal of Child Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ajmg.c.31325","article-title":"Nosology and epidemiology in autism: classification counts","volume":"160C","author":"Fisch","year":"2012","journal-title":"American Journal of Medical Genetics. Part C, Seminars in Medical Genetics"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/med\/9780195371826.003.0007","volume-title":"Autism Spectrum Disorders","author":"Fombonne","year":"2011"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0057|cit57","unstructured":"Fombonne E MacFarlane H Salem AC Epidemiological surveys of ASD: advances and remaining challenges Journal of Autism and Developmental Disorders 10.1007\/s10803-021-05005-9 33864555"},{"issue":"7","key":"10.1002\/14651858.CD013845.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1177\/1362361315583818","article-title":"Characterizing the daily life, needs, and priorities of adults with autism spectrum disorder from Interactive Autism Network data","volume":"19","author":"Gotham","year":"2015","journal-title":"Autism"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0059|cit59","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0060|cit60","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD013845.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archgenpsychiatry.2011.76","article-title":"Genetic heritability and shared environmental factors among twin pairs with autism","volume":"68","author":"Hallmayer","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD013845.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1007\/s10803-021-05237-9","article-title":"Decades of progress in the psychopharmacology of autism spectrum disorder","volume":"51","author":"Henneberry","year":"2021","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0064|cit64","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In:\u00a0Higgins JP,\u00a0Green S, editor(s).\u00a0Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0065|cit65","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0066|cit66","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0067|cit67","first-page":"166","article-title":"Memantine: a review of possible uses in child and adolescent psychiatry","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"Journal of the Canadian Academy of Child and Adolescent Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013845.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007992.pub2","article-title":"Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)","author":"James","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0069|cit69","unstructured":"Chelation for autism spectrum disorder (ASD) Cochrane Database of Systematic Reviews 2015 5 10.1002\/14651858.CD010766.pub2 26114777"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1517\/14740330802528420","article-title":"Memantine: a comprehensive review of safety and efficacy","volume":"8","author":"Kavirajan","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/1362361315588200","article-title":"Which terms should be used to describe autism? Perspectives from the UK autism community","volume":"20","author":"Kenny","year":"2016","journal-title":"Autism"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0072|cit72","volume-title":"NEPSY-II","author":"Korkman","year":"2007"},{"issue":"7","key":"10.1002\/14651858.CD013845.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/00003088-200746070-00005","article-title":"Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach","volume":"46","author":"Kornhuber","year":"2007","journal-title":"Clinical Pharmacokinetics"},{"issue":"9920","key":"10.1002\/14651858.CD013845.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","article-title":"Autism","volume":"383","author":"Lai","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0075|cit75","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0076|cit76","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD013845.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaac.2017.03.013","article-title":"What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis","volume":"56","author":"Loomes","year":"2017","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview \u2013 Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0079|cit79","volume-title":"ADOS-2: Autism Diagnostic Observation Schedule, Manual (Part 1): Modules 1\u20134","author":"Lord","year":"2012"},{"issue":"11","key":"10.1002\/14651858.CD013845.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1\u201316","DOI":"10.15585\/mmwr.ss7011a1","article-title":"Prevalence and characteristics of autism spectrum disorder among children aged 8 years \u2014 Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018","volume":"70","author":"Maenner","year":"2021","journal-title":"MMWR Surveillance Summaries"},{"issue":"6","key":"10.1002\/14651858.CD013845.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/MOP.0b013e32834c9282","article-title":"Common neurological co-morbidities in autism spectrum disorders","volume":"23","author":"Maski","year":"2011","journal-title":"Current Opinions in Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/aur.2286","article-title":"Autism spectrum disorder prevalence in children aged 12\u201313 years from the Longitudinal Study of Australian Children","volume":"13","author":"May","year":"2020","journal-title":"Autism Research"},{"issue":"9","key":"10.1002\/14651858.CD013845.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011611.pub2","article-title":"Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults","author":"McCloud","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"41","key":"10.1002\/14651858.CD013845.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19410","article-title":"Systematic review of tools to measure outcomes for young children with autism spectrum disorder","volume":"19","author":"McConachie","year":"2015","journal-title":"Health Technology Assessments"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1037\/1040-3590.15.4.578","article-title":"The Children's Yale-Brown Obsessive-Compulsive Scale: item structure in an outpatient setting","volume":"15","author":"McKay","year":"2003","journal-title":"Psychological Assessment"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub6","article-title":"Memantine for dementia","author":"McShane","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003498.pub3","article-title":"Gluten and casein-free diets for autistic spectrum disorder","author":"Millward","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0088|cit88","first-page":"106","article-title":"Memantine versus methylphenidate in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial","volume":"10","author":"Mohammadi","year":"2015","journal-title":"Iran Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"e2687","DOI":"10.1002\/hup.2687","article-title":"The effect of memantine in adult patients with attention deficit hyperactivity disorder","volume":"34","author":"Mohammadzadeh","year":"2019","journal-title":"Human Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD013845.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chemical Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.jcp.0000270082.30500.69","article-title":"Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism","volume":"27","author":"Niederhofer","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003497.pub2","article-title":"Combined vitamin B6-magnesium treatment in autism spectrum disorder","author":"Nye","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00415-006-0374-x","article-title":"Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease","volume":"254","author":"Ott","year":"2007","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/cap.2006.16.517","article-title":"A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders","volume":"16","author":"Owley","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1586\/erp.12.29","article-title":"Autism spectrum disorders: a review of measures for clinical, health services and cost-effectiveness applications","volume":"12","author":"Payakachat","year":"2012","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD013845.pub2-BIB0097|cit97","first-page":"5","article-title":"American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. 2nd edition","volume":"164","author":"Rabins","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013845.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0304-3940(01)01872-9","article-title":"The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner","volume":"306","author":"Rammes","year":"2001","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/nyas.12318","article-title":"Treatment of pediatric anxiety disorders","volume":"1304","author":"Rapp","year":"2013","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1-2","key":"10.1002\/14651858.CD013845.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/0006-8993(88)91630-7","article-title":"Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line","volume":"443","author":"Reiser","year":"1988","journal-title":"Brain Research"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0101|cit101","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"8","key":"10.1002\/14651858.CD013845.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00702-014-1216-0","article-title":"The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment","volume":"121","author":"Rojas","year":"2014","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fped.2014.00087","article-title":"The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review","volume":"2","author":"Rossignol","year":"2014","journal-title":"Frontiers in Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD013845.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1362361313510069","article-title":"Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder","volume":"19","author":"Scahill","year":"2015","journal-title":"Autism"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0106|cit106","volume-title":"The Childhood Autism Rating Scale (CARS): For Diagnostic Screening and Classification of Autism","author":"Schopler","year":"1986"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0107|cit107","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"749796","DOI":"10.1155\/2012\/749796","article-title":"Memantine as an augmentation therapy for anxiety disorders","volume":"2012","author":"Schwartz","year":"2012","journal-title":"Case Reports in Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/syn.20472","article-title":"Memantine agonist action at dopamine D2High receptors","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"issue":"9","key":"10.1002\/14651858.CD013845.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s10803-006-0307-7","article-title":"Change in autism symptoms and maladaptive behaviors in adolescents and adults with an autism spectrum disorder","volume":"37","author":"Shattuck","year":"2007","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"8","key":"10.1002\/14651858.CD013845.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1007\/s10803-011-1399-2","article-title":"Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice","volume":"42","author":"Siegel","year":"2012","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"12","key":"10.1002\/14651858.CD013845.pub2-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003681.pub3","article-title":"Auditory integration training and other sound therapies for autism spectrum disorders (ASD)","author":"Sinha","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013845.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"966","DOI":"10.4088\/JCP.12m08252","article-title":"Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"Smith","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0114|cit114","volume-title":"Vineland-3: Vineland Adaptive Behavior Scales","author":"Sparrow","year":"2016"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4306\/pi.2013.10.4.421","article-title":"A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life","volume":"10","author":"Strzelecki","year":"2013","journal-title":"Psychiatry Investigation"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/15622975.2011.623716","article-title":"A pilot open label prospective study of memantine monotherapy in adults with ADHD","volume":"14","author":"Surman","year":"2013","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/cia.s6666","article-title":"Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias","volume":"4","author":"Thomas","year":"2009","journal-title":"Clinical Interventions in Aging"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1570159X113116660046","article-title":"The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome","volume":"12","author":"Uzunova","year":"2014","journal-title":"Current Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","article-title":"A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease","volume":"21","author":"Van Dyck","year":"2007","journal-title":"Alzheimer Disease & Associated Disorders"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1017\/S1092852913000941","article-title":"Clinical features, developmental course, and psychiatric comorbidity of adult autism spectrum disorders","volume":"19","author":"Vannucchi","year":"2014","journal-title":"CNS Spectrums"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10803-013-1913-9","article-title":"Gender and age differences in the core triad of impairments in autism spectrum disorders: a systematic review and meta-analysis","volume":"44","author":"Van Wijngaarden-Cremers","year":"2014","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD013845.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/YCO.0000000000000133","article-title":"An update on anxiety in youth with autism spectrum disorders","volume":"28","author":"Vasa","year":"2015","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-clinpsy-032813-153710","article-title":"From Kanner to DSM-5: autism as an evolving diagnostic concept","volume":"10","author":"Volkmar","year":"2014","journal-title":"Annual Review of Clinical Psychology"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0125|cit125","volume-title":"Wechsler Intelligence Scale for Children","author":"Wechsler","year":"2014"},{"issue":"5","key":"10.1002\/14651858.CD013845.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"e36981","DOI":"10.1371\/journal.pone.0036981","article-title":"The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome","volume":"7","author":"Wei","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0127|cit127","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization (WHO)","year":"1992"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0128|cit128","unstructured":"World Health Organization International classification of diseases for mortality and morbidity statistics (11th Revision) www.icd.who.int\/browse11\/l-m\/en"},{"issue":"4","key":"10.1002\/14651858.CD013845.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003495.pub3","article-title":"Intravenous secretin for autism spectrum disorders (ASD)","author":"Williams","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013845.pub2-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004677.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","author":"Williams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jpc.12805","article-title":"Regression in autism spectrum disorders","volume":"51","author":"Williams","year":"2015","journal-title":"Journal of Paediatrics and Child Health"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0132|cit132","volume-title":"EVT-3: Expressive Vocabulary Test","author":"Williams","year":"2018"},{"issue":"9093","key":"10.1002\/14651858.CD013845.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(97)09218-0","article-title":"The autistic spectrum","volume":"350","author":"Wing","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013845.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/1469-7610.00023","article-title":"The Diagnostic Interview for Social and Communication Disorders: background, inter-rater reliability and clinical use","volume":"43","author":"Wing","year":"2002","journal-title":"Journal of Child Psychology and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.rasd.2011.06.008","article-title":"A systematic review of the diagnostic stability of autism spectrum disorder","volume":"6","author":"Woolfenden","year":"2012","journal-title":"Research in Autism Spectrum Disorders"},{"key":"10.1002\/14651858.CD013845.pub2-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD) Cochrane Database of Systematic Reviews 2016 10 10.1002\/14651858.CD010922.pub2 27737490","DOI":"10.1002\/14651858.CD010922.pub2"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Singh","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013845.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/aur.1977","article-title":"Association between schizophrenia and autism spectrum disorder: a systematic review and meta-analysis","volume":"11","author":"\u00a0Zou","year":"2018","journal-title":"Autism Research"},{"issue":"1","key":"10.1002\/14651858.CD013845.pub2-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013845","article-title":"Memantine for autism spectrum disorder","author":"Brignell","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T19:51:00Z","timestamp":1754596260000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013845.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":139,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013845.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}